Personalis, Inc. (NASDAQ:PSNL – Get Rating) was the target of a significant drop in short-term interest in June. As of June 30, there was short interest totaling 1,130,000 shares, a decrease of 44.9% from the June 15 total of 2,050,000 shares. Approximately 3.1% of the company’s shares are sold short. Based on an average trading volume of 637,800 shares, the short interest ratio is currently 1.8 days.

Insider trading at Personalis

In other news, General Counsel Stephen Michael Moore sold 5,733 shares of Personalis in a transaction that took place on Monday May 2. The shares were sold at an average price of $5.53, for a total value of $31,703.49. Following the transaction, the General Counsel now directly owns 76,381 shares of the company, valued at $422,386.93. The transaction was disclosed in a legal filing with the SEC, accessible via this hyperlink. Insiders sold a total of 28,354 shares of the company valued at $113,919 over the past ninety days. Company insiders own 7.50% of the company’s shares.

Hedge funds weigh on Personalis

Several large investors have recently bought and sold shares of the stock. Hsbc Holdings PLC increased its stake in Personalis by 14.6% during the 1st quarter. Hsbc Holdings PLC now owns 17,710 shares of the company valued at $146,000 after buying an additional 2,262 shares in the last quarter. Zurcher Kantonalbank Zurcher Kantonalbank increased its stake in Personalis by 24.5% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,549 shares of the company valued at $208,000 after purchasing an additional 2,866 shares in the last quarter. Green Alpha Advisors LLC increased its stake in Personalis by 12.5% ​​during the 1st quarter. Green Alpha Advisors LLC now owns 34,045 shares of the company valued at $279,000 after purchasing an additional 3,790 shares in the last quarter. Amalgamated Bank acquired a new position in Personalis during Q1 worth $37,000. Finally, Bank of America Corp DE increased its stake in Personalis by 5.1% during the 1st quarter. Bank of America Corp DE now owns 98,383 shares of the company valued at $805,000 after buying an additional 4,734 shares in the last quarter. 86.47% of the shares are currently held by institutional investors and hedge funds.

A Wall Street analyst gives his opinion

A d Tradewins

The safest option in the trades!

If you’re new to trading, you’ve probably heard the wrong word about options, that they’re risky, unpredictable, or difficult. And it couldn’t be more wrong! With the Hughes Optioneering strategy, you will soon learn that the safest option for new accounts is the options themselves!

A number of research analysts have recently commented on the stock. HC Wainwright lowered its price target on shares of Personalis from $38.00 to $30.00 in a Thursday, May 5 research report. Citigroup lowered its price target on shares of Personalis from $18.00 to $14.00 in a Thursday, May 5 research report. Two analysts rated the stock with a hold rating and five gave the company a buy rating. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $24.86.

Performance of custom actions

Shares of Personalis traded down $0.05 on Friday, hitting $4.05. The stock had a trading volume of 323,415 shares, compared to an average volume of 683,850. The company’s 50-day moving average price is $3.96 and its two-hundred-day moving average price is $7.59. Personalis has a fifty-two week low of $3.13 and a fifty-two week high of $23.04. The stock has a market capitalization of $184.07 million, a P/E ratio of -2.23 and a beta of 1.67.

Personalis (NASDAQ:PSNL – Get Rating) last released quarterly earnings data on Wednesday, May 4. The company reported ($0.63) earnings per share for the quarter, missing analyst consensus estimates of ($0.57) by ($0.06). Personalis had a negative return on equity of 25.70% and a negative net margin of 101.49%. The company posted revenue of $15.23 million in the quarter, compared to analyst estimates of $14.84 million. In the same quarter a year earlier, the company posted ($0.29) earnings per share. As a group, stock analysts expect Personalis to post earnings per share of -2.52 for the current fiscal year.

About Personalis

(Get a rating)

Personalis, Inc operates as a worldwide cancer genomics company. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for the tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tissue-based tumor profiling; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offer for personalized tumor monitoring for patients; NeXT Dx Test, a cancer genomic profiling test enabling composite biomarkers for cancer therapy; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities.

Featured Articles

This instant news alert was powered by MarketBeat’s storytelling science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Personalis right now?

Before you consider Personalis, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off… and Personalis wasn’t on the list.

Although Personalis currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here